The addition of DPP-4 inhibitors to sulphonylureas in people with type 2 diabetes is associated with a 50% increased risk of hypoglycaemia, new research has revealed. While the link is not new, this systematic review and meta-analysis, published in the British Medical Journal is the first to measure the magnitude of the risk. “This meta-analysis ...
Timely reminder to watch hypoglycaemia risk with DPP-4 and sulphonylureas combination
2 Jun 2016